Ch806 was stably expressed in CHO cells and exhibited antigen binding specificity and affinity identical to that of its parent murine antibody. exposed that125I-labelled ch806 failed to display any significant tumour retention. However, specific and long term tumour localisation of’111In-labelled ch806 was shown with uptake of 31%ID g1and a tumour to blood percentage of 5 : 1 observed at 7 days postinjection.In VX-745 vivotherapy studies with ch806 proven significant antitumour effects on founded de2-7 EGFR xenografts in BALB/c nude mice compared to control, and both murine 806 and the anti-EGFR 528 antibodies. These results support a potential restorative part of ch806 in the treatment of appropriate EGFR-expressing tumours, and warrants further investigation of the potential of ch806 like a restorative agent. Keywords:EGFR, chimeric antibody, immunotherapy, EGFRvIII Overexpression of the epidermal growth element receptor (EGFR) has been observed in many tumours including the breast, lung, colon, prostate, head and neck, and mind, and improved EGFR expression regularly correlates with more aggressive clinical program (Nicholsonet al, 2001;Arteaga, 2002;Mendelsohn, 2002). This overexpression of the receptor is commonly the result of theEGFRgene amplification (Hendler and Ozanne, 1984;Sainsburyet al, 1987;Salomonet al, 1995).EGFRgene amplification and subsequent overexpression of the EGFR protein is particularly prevalent in gliomas, the most common primary tumour of the central KIAA1235 nervous system (Wikstrandet al, 1997). Indeed, the highly malignant glioblastoma VX-745 multiforme exhibitsEGFRgene amplification at a rate of recurrence of 4050%, with many tumours also exhibiting structural rearrangements of theEGFR(Voldborget al, 1997). The most common of these variantEGFRgenes consists of an in-frame 801 bp deletion that removes exons 27 of theEGFRgene (Sugawaet al, 1990;Wonget al, 1992;Fredericket al, 2000). This producing receptor, known as the de2-7 EGFR, does not bind ligand but displays a low level of constitutive activity and imparts a significantin vivogrowth advantage to a number of tumour types including the breast, lung and particularly gliomas (Nishikawaet al, 1994;Wikstrandet al, 1998;Tanget al, 2000). Because the EGFR is definitely overexpressed in many types of malignancy, and its blockade often inhibits tumour growth, this receptor is a rational target for novel malignancy therapeutics. Potential anti-EGFR therapeutics include anti-EGFR antibodies (Satoet al, 1987), EGFR-ligand conjugates, EGFR immunoconjugates, small molecular excess weight tyrosine kinase inhibitors (Fryet al, 1994;Levitzki and Gazit, 1995), dominant-negative EGFR constructs, antisense EGFR oligonucleotides, all of which are capable of blocking EGFR function (de Bono and Rowinsky, 2002;Herbst and Langer, 2002;Herbst and Shin, 2002;Wakeling, 2002). A number of antibodies directed to the extracellular website of the EGFR have been tested in the medical center including EMD 55900 (Bieret al, 2001), ABX-EGF (Yanget al, 2001) and IMC-C225 (Mendelsohn, 1997) with some antitumour activity demonstrated in individuals. The most clinically advanced of these is definitely IMC-225, that is currently in Phase II/III clinical tests and has recently been authorized by the FDA for use in conjunction with irinotecan in individuals with irinotecan refractory colorectal malignancy (Stragliottoet al, 1996;Herbst and Langer, 2002;Lynch and Yang, 2002). Significant uptake in normal tissue such as the liver and skin is a potential limitation of antibodies focusing on the wild-type (wt) EGFR (Divgiet al, 1991;Busamet al, 2001). While focusing on of normal cells usually generates manageable side effects such as pores and skin rash, it does mean these antibodies are improper for coupling with cytotoxic providers or radioisotopes. Several antibodies have also been developed that specifically target the tumour-specific de2-7 EGFR (Humphreyet al, 1990;Hillset al, 1995;Wikstrandet al, 1995). These antibodies are directed to the unique junctional peptide VX-745 created from the deletion event in the de2-7 EGFR and therefore are specific for this receptor and don’t bind the wt EGFR. We recently described a novel monoclonal antibody (mAb 806) generated by immunising mice with cells expressing the full-length de2-7 EGFR (Luworet al, VX-745 2001;Mishimaet al, 2001;Johnset al, 2002;Jungbluthet al, 2003). Scatchard analysis shown mAb 806 binds only approximately 10% of the wt EGFR on the surface of A431 cells, a cell collection that over-expresses the wt EGFR (Johnset al, 2002). In the absence of ligand, the majority of wt EGFR within VX-745 the cell surface is definitely in an inactive or tethered form. In order to form active dimers, the EGFR untethers and undergoes a conformational switch. The mAb 806 epitope is only exposed when the receptor is in this transient state between inactive and active dimer (Johnset al, 2004). Therefore, at any given time point, mAb 806 can.
Ch806 was stably expressed in CHO cells and exhibited antigen binding specificity and affinity identical to that of its parent murine antibody
